Elsevier

Seminars in Oncology

Volume 42, Issue 6, December 2015, Pages e83-e98
Seminars in Oncology

Current Clinical Practice
Four Difficult Thyroid Cancer Cases: Incorporating Medical Therapies

https://doi.org/10.1053/j.seminoncol.2015.09.035Get rights and content

Section snippets

Case No. 1

A 73-year-old male alcoholic patient with chronic obstructive pulmonary disease (COPD), obesity, and diabetes is evaluated in the intensive care unit for an enlarging neck mass. He was intubated for airway protection after he presented with syncope and hypoxia (ie, pickwickian syndrome in the setting of an enlarging neck mass). An ultrasound of the neck revealed a 6-cm heterogeneously cystic mass with enlarged locoregional bilateral cervical lymph nodes. The neck mass was biopsied and confirmed

Conclusions

This case series presented several opportunities for medical therapies to concurrently enhance the surgical management of difficult thyroid cancer scenarios. Specifically, case discussions focused on the evidence for various medical therapies (ie, cytotoxic chemotherapy, targeted therapy, and hormonal modulations). Treatment paradigms in thyroid cancers are shifting to incorporate new medical modalities of care. These paradigmatic changes should focus on how novel therapies will enhance the

First page preview

First page preview
Click to open first page preview

REFERENCES (56)

  • M.S. Brose et al.

    Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma

    Expert Rev Anticancer Ther

    (2012)
  • N. Besic et al.

    Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma

    Thyroid

    (2013)
  • Y. Ito et al.

    Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component

    Endocr J

    (2012)
  • J. Tennvall et al.

    Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group

    Cancer

    (1994)
  • K. Shimaoka et al.

    A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma

    Cancer

    (1985)
  • G. Crouzeix et al.

    Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma

    J Clin Endocrinol Metab

    (2012)
  • M. Schlumberger et al.

    Lenvatinib versus placebo in radioiodine-refractory thyroid cancer

    N Engl J Med

    (2015)
  • J. Honings et al.

    The management of thyroid carcinoma invading the larynx or trachea

    Laryngoscope

    (2010)
  • R.P. McCarthy et al.

    Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas

    Clin Cancer Res

    (2006)
  • R. Dadu et al.

    Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib

    J Clin Endocrinol Metab

    (2014)
  • K.B. Kim et al.

    Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation

    Thyroid

    (2013)
  • F. Santini et al.

    Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer

    J Clin Endocrinol Metab

    (2002)
  • S. Moritani

    Surgical management of laryngeal invasion by papillary thyroid carcinoma: a retrospective analysis

    Thyroid

    (2015)
  • J.E. Maxwell et al.

    Medical management of metastatic medullary thyroid cancer

    Cancer

    (2014)
  • C. Mahler et al.

    Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide

    Clin Endocrinol

    (1990)
  • E. Modigliani et al.

    Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma

    Clin Endocrinol

    (1992)
  • E.T. Janson et al.

    Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon

    Acta Oncol

    (1993)
  • E. Skoura

    Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging

    Int J Endocrinol Metab

    (2013)
  • Cited by (0)

    Conflicts of interest: none.

    View full text